In Vivo Measurement of Vesicular Monoamine Transporter Type 2 Density in Parkinson Disease with 18F-AV-133
Authors:
- Nobuyuki OkamuraNONobuyuki Okamura
- Victor L. VillemagneVVVictor L. Villemagne
- John DragoJDJohn Drago
- Svetlana PejoskaSPSvetlana Pejoska
- Rajinder K. DhamijaRDRajinder K. Dhamija
- Rachel S. MulliganRMRachel S. Mulligan
- Julia R. EllisJEJulia R. Ellis
- Uwe AckermannUAUwe Ackermann
- Graeme O'KEefeGOGraeme O'KEefe
- Gareth JonesGJGareth Jones
- Hank F. KungHKHank F. Kung
- Michael J. PontecorvoMPMichael J. Pontecorvo
Open Access
- 15 January 2010
- journal article
- Published by Society of Nuclear Medicine in Journal of Nuclear Medicine
- Vol. 51 (2) , 223-228
Abstract
PET provides a noninvasive means to evaluate the functional integrity of the presynaptic monoaminergic system in the living human brain. Methods: In this study, a novel 18F-labeled tetrabenazine derivative, 18F-(+)fluoropropyldihydrotetrabenazine (18F-AV-133), was used for the noninvasive assessment of the vesicular monoamine transporters type 2 (VMAT2) in 17 Parkinson disease (PD) patients and 6 healthy controls. The binding potential (BP) of 18F-AV-133 was calculated using Logan graphical analysis. Voxel-based and volume-of-interest–based analyses of BP images were performed to examine brain regional reductions in VMAT2 density in PD. Results: VMAT2 BP was decreased by 81% in the posterior putamen, 70% in the anterior putamen, and 48% in the caudate nucleus of PD patients. Voxel-based analysis demonstrated VMAT2 reductions in the striatum and mid brain of PD patients. Furthermore, VMAT2 BPs in the caudate nuclei significantly correlated with the clinical severity of PD. Conclusion: These findings indicate that the novel 18F-labeled ligand 18F-AV-133 can sensitively detect monoaminergic terminal reductions in PD patients. Studies with 18F-AV-133 may allow the presymptomatic identification of individuals with disorders characterized by degeneration of dopaminergic nigrostriatal afferents.Keywords
This publication has 25 references indexed in Scilit:
- Dihydrotetrabenazine positron emission tomography imaging in early, untreated Parkinson's diseaseAnnals of Neurology, 2008
- Characterization of optically resolved 9-fluoropropyl-dihydrotetrabenazine as a potential PET imaging agent targeting vesicular monoamine transportersNuclear Medicine and Biology, 2007
- Positron Emission Tomography of Monoaminergic Vesicular Binding in Aging and Parkinson DiseaseJournal of Cerebral Blood Flow & Metabolism, 2006
- Fluoroalkyl derivatives of dihydrotetrabenazine as positron emission tomography imaging agents targeting vesicular monoamine transportersNuclear Medicine and Biology, 2006
- Striatal monoamine terminals in Lewy body dementia and Alzheimer's diseaseAnnals of Neurology, 2004
- Role of dopamine transporter imaging in routine clinical practiceMovement Disorders, 2003
- Loss of Striatal Vesicular Monoamine Transporter Protein (VMAT2) in Human Cocaine UsersAmerican Journal of Psychiatry, 2003
- Progression of dopaminergic degeneration in Parkinson's disease and atypical parkinsonism: A longitudinal β‐CIT SPECT studyMovement Disorders, 2001
- Immunochemical Analysis of Vesicular Monoamine Transporter (VMAT2) Protein in Parkinson's DiseaseExperimental Neurology, 1999
- Effects of dopaminergic drug treatments on in vivo radioligand binding to brain vesicular monoamine transportersNuclear Medicine and Biology, 1996